US20200325519A1 - Biomarker assay for use in monitoring autism - Google Patents
Biomarker assay for use in monitoring autism Download PDFInfo
- Publication number
- US20200325519A1 US20200325519A1 US16/761,926 US201816761926A US2020325519A1 US 20200325519 A1 US20200325519 A1 US 20200325519A1 US 201816761926 A US201816761926 A US 201816761926A US 2020325519 A1 US2020325519 A1 US 2020325519A1
- Authority
- US
- United States
- Prior art keywords
- sample
- asd
- protein kinase
- levels
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012544 monitoring process Methods 0.000 title claims abstract description 22
- 208000020706 Autistic disease Diseases 0.000 title description 11
- 238000003556 assay Methods 0.000 title description 11
- 206010003805 Autism Diseases 0.000 title description 8
- 239000000090 biomarker Substances 0.000 title description 5
- 208000029560 autism spectrum disease Diseases 0.000 claims abstract description 144
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims abstract description 103
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims abstract description 103
- 239000000523 sample Substances 0.000 claims abstract description 76
- 238000011282 treatment Methods 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 29
- 230000004044 response Effects 0.000 claims abstract description 24
- 239000013068 control sample Substances 0.000 claims abstract description 10
- 210000002966 serum Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 210000003296 saliva Anatomy 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 230000009266 disease activity Effects 0.000 claims description 2
- 102000001253 Protein Kinase Human genes 0.000 description 12
- 108060006633 protein kinase Proteins 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000003827 upregulation Effects 0.000 description 7
- 206010010356 Congenital anomaly Diseases 0.000 description 6
- 238000004891 communication Methods 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 4
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 4
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 4
- 208000008454 Hyperhidrosis Diseases 0.000 description 4
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 208000008312 Tooth Loss Diseases 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 210000004489 deciduous teeth Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 3
- 229960004064 bumetanide Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 208000036640 Asperger disease Diseases 0.000 description 2
- 201000006062 Asperger syndrome Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 108010025076 Holoenzymes Proteins 0.000 description 2
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 2
- 201000006347 Intellectual Disability Diseases 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 206010052642 Iris coloboma Diseases 0.000 description 2
- 206010050183 Macrocephaly Diseases 0.000 description 2
- 208000005767 Megalencephaly Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000012202 Pervasive developmental disease Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 210000000877 corpus callosum Anatomy 0.000 description 2
- 210000000720 eyelash Anatomy 0.000 description 2
- 208000011318 facial edema Diseases 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 230000009760 functional impairment Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000037315 hyperhidrosis Effects 0.000 description 2
- 229960002491 ibudilast Drugs 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000036562 nail growth Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000004417 patella Anatomy 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003989 repetitive behavior Effects 0.000 description 2
- 208000013406 repetitive behavior Diseases 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000003997 social interaction Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 210000002978 thoracic duct Anatomy 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- LNOVHERIIMJMDG-XZXLULOTSA-N 2-[(3r,6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O LNOVHERIIMJMDG-XZXLULOTSA-N 0.000 description 1
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 1
- 101150044980 Akap1 gene Proteins 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102100038165 Chromodomain-helicase-DNA-binding protein 8 Human genes 0.000 description 1
- 102000005685 Cyclic AMP-Dependent Protein Kinase Type I Human genes 0.000 description 1
- 108010084920 Cyclic AMP-Dependent Protein Kinase Type I Proteins 0.000 description 1
- 102000018610 Cyclic AMP-Dependent Protein Kinase Type II Human genes 0.000 description 1
- 108010066606 Cyclic AMP-Dependent Protein Kinase Type II Proteins 0.000 description 1
- RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMXB-A Chemical compound COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 description 1
- 241001050985 Disco Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000883545 Homo sapiens Chromodomain-helicase-DNA-binding protein 8 Proteins 0.000 description 1
- -1 IL-1β Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 241000244169 Nemertea Species 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 208000036353 Rett disease Diseases 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 101710184528 Scaffolding protein Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 1
- 229960004047 acamprosate Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022379 autosomal dominant Opitz G/BBB syndrome Diseases 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000024825 childhood disintegrative disease Diseases 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- CJUDSKIRZCSXJA-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 CJUDSKIRZCSXJA-UHFFFAOYSA-M 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229960005559 sulforaphane Drugs 0.000 description 1
- 235000015487 sulforaphane Nutrition 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000003976 synaptic dysfunction Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
Definitions
- the present invention relates to a biomarker assay for use in monitoring autism spectrum disorders (ASD), in particular ASD phenotype 1. Furthermore, the assay of the invention is also useful for diagnosing ASD phenotype 1.
- ASD autism spectrum disorders
- PKA cAMP-dependent protein kinase
- R regulatory subunit
- C active catalytic kinase subunit
- Most of the effects of cAMP in eukaryotic systems are the result of phosphorylation of proteins at serine or threonine residues by PKA.
- PKA is localized subcellularly by binding to multidomain scaffolding proteins known as AKAPs which bind to the R subunits of the holoenzyme (Pearce, L. R., D. Komander, and D. R. Alessi, The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol, 2010. 11 (1): p. 9-22).
- PKA plays a key role in neurodevelopment.
- Autism spectrum disorder is a group of neurodevelopmental disorders frequently characterized by impairments in social interactions, difficulties with language and communication, and the presence of repetitive, perseverative behaviors (Abrahams B S, Geschwind D H; Advances in autism genetics: on the threshold of a new neurobiology; Nat Rev Genet. 2008 June; 9(6):493), (Zoghbi H Y, Bear M F; Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities; Cold Spring Harb Perspect Biol. 2012 Mar. 1; 4(3)). Characteristic symptoms or behavioral traits of ASD typically appear during the first three years of life and remain present throughout life in the vast majority of patients. Intensity of symptoms may vary from patient to patient and may decrease as the patient develops adaptative skills. Environmental factors, Developmental (transition to puberty . . . ) or comorbidities such as epilepsia can also result in a worsening of symptoms.
- ASD is characterized by two sets of core impairments: persisting deficits of social communication and interaction and restricted and repetitive behaviors, interests, activities.
- DSM-IV-Text Revision DSM-IV-TR 4th Edition. Washington, D.C.: American Psychiatric Association; 2000. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders.
- DSM-5 introduced significant changes. In the diagnostic criteria, language abilities not employed in social communication have been de-emphasized.
- DSM-5 additionally requires to specify where patient fits within three levels of increasing severity of ASD, from (1) (“requiring support”) to (2) (“requiring substantial support”) up to (3) (“requiring very substantial support”).
- the problem to be solved is thus the provision of means to efficiently and easily identify phenotypes of ASD patients and monitor the activity of their disease with the help of easy-to-use biomarker assays.
- the present invention solves this problem by providing protein kinase A for use in diagnosing autism spectrum disorder (ASD) phenotype 1 in an ASD patient wherein protein kinase A levels are measured in a sample of the patient and wherein ASD phenotype 1 is diagnosed if the measured protein kinase A levels are lower than protein kinase A levels in an age and sex-matched control sample.
- ASSD autism spectrum disorder
- protein kinase A for use in monitoring variation in ASD severity in an ASD patient, wherein protein kinase A levels are measured in a sample of the patient and wherein an increase in ASD severity is characterized by a decrease of protein kinase A levels compared to protein kinase A levels measured in previous samples of the patient.
- the problem is solved by a method for diagnosing ASD phenotype 1 in an ASD patient, the method comprising
- the present invention relates to protein kinase A for use in diagnosing autism spectrum disorder (ASD) phenotype 1 in an ASD patient wherein protein kinase A levels are measured in a sample of the patient and wherein ASD phenotype 1 is diagnosed if the measured protein kinase A levels are lower than protein kinase A levels in an age and sex-matched control sample.
- ASSD autism spectrum disorder
- autism spectrum disorder is understood to cover a family of neurodevelopmental disorders characterized by deficits in social communication and interaction and restricted, repetitive patterns of behavior, interests or activities.
- autism spectrum disorder is understood to cover a family of neurodevelopmental disorders characterized by deficits in social communication and interaction and restricted, repetitive patterns of behavior, interests or activities.
- autism spectrum disorder is used interchangeably.
- ASD Alzheimer's disease
- DSM-5 Diagnostic and Statistical Manual of Mental Disorders
- ASD patients may have been diagnosed according to standardized assessments tools including but not limited to DSM IV, ICD-9, ICD-10, DISCO, ADI-R, ADOS, CHAT.
- patients may have a well-established DSM-IV diagnosis of autistic disorder, Asperger's disorder, or pervasive developmental disorder not otherwise specified (PDD-NOS).
- DSD-NOS pervasive developmental disorder not otherwise specified
- Protein kinase A is a family of cAMP-dependent protein kinases consisting of two catalytic and two regulatory subunits. As understood herein, the term “protein kinase A” covers any member of this enzyme family. In particular, the term is understood to refer to the two major types of mammalian protein kinase A, type I and type II (PKA I and PKA II). These kinases are distinguished by the presence of different R subunits termed RI and RII.
- the present invention envisages not only measurement of holoenzyme of protein kinase A, but also of each of the subunits. In a preferred embodiment isoenzyme protein kinase A located in serum is measured.
- Measurement of protein kinase A can be performed using any method known to the skilled person. Examples of measurement methods include immunoassays, immunofluorescence assays, enzyme-linked immunosorbent assays (ELISA), lateral flow assays, radioimmunoassays (RIA) and magnetic immunoassays (MIA).
- protein kinase A levels are measured using a modified MESACUP Protein Kinase A Activity Assay.
- protein kinase A levels are measured by ELISA using an anti-protein kinase A-antibody.
- the sample of the patient may be any sample of a body fluid.
- the sample is selected from a blood sample, serum sample, plasma sample, saliva sample, a urine sample.
- the sample may have been processed to facilitate measurement of protein kinase A, e.g., by purification or by separation of individual components in the case of a whole-blood sample.
- age and sex-matched control sample refers to a sample taken from an individual or a group of healthy subjects having an age and sex corresponding to the ASD patient.
- ASD phenotype 1 patients can be defined by the following clinical signs and symptoms: having: 1) at least 1 mandatory characteristics: enlarged head size verses control population characterized by at least one standard deviation above the mean head circumference (HC) at 24 months and/or formal macrocephaly (HC>97% of the general population) and/or cyclical aggravation of core or ancillary autism symptoms potentiated by periods of infectious events, deciduous tooth loss, post-traumatic injury, endogenous and exogenous temperature variation; 2) and at least 2, most preferably at least 3 of the following 20 characteristics: accelerated hair and nail growth versus control population; Increased tendency to present with lighter colors of skin and eyes as compared to individuals of the same ethnicity; Substantially longer eyelashes than control subjects of the same ethnicity; At least 5 non-contiguous areas of hypopigmented skin, particularly presenting on the back of the patient; Signs of edema during periods of infectious events, deciduous tooth loss
- ASD phenotype 1 patients can be characterized by upregulation of Nrf2 transcriptional factor and clinical signs of heightened expression of proliferation-associated pathways. At the same time, these patients show an upregulation of pathways involved in adaptation to stress, apoptosis or cell differentiation, cell proliferation, cell cycle progression, cell division and differentiation (in particular but not limited to PI3K, AKT, mTOR/MAPK, ERK/JNK-P38).
- proinflammatory cytokines TNF- ⁇ , IL-6, IL-1 ⁇ , IL-17A, IL-22 and GM-CSF
- Th1 cytokine INF- ⁇
- chemokine IL-8
- Th2 cytokines IL-4, IL-5 and IL-10
- the Th1/Th2 ratio may be significantly increased in phenotype 1 patients.
- the present invention provides for the first time a biomarker that can be used to identify and/or diagnose ASD phenotype 1 in an ASD patient. Consequently, the present invention provides a fast and easy method for the identification of ASD phenotype 1 patients.
- the present invention also relates to protein kinase A for use in monitoring variation in ASD severity in an ASD patient, wherein protein kinase A levels are measured in a sample of the patient and wherein an increase in ASD severity is characterized by a decrease of protein kinase A levels compared to protein kinase A levels measured in previous samples of the patient.
- the present invention provides protein kinase A for use in monitoring variation in ASD severity in an ASD phenotype 1 patient.
- ASD phenotype 1 patients may also be identified with the help of a challenge test as described in PCT/EP2018/080372. Briefly, the concept of a challenge test is based on administration of an Nrf2-activator to an ASD patient. In ASD phenotype 1 patients, who already show an upregulation of the respective pathways, further activation of Nrf2 will lead to a worsening of core symptoms. Consequently, ASD phenotype 1 patients may be identified by a negative response in a challenge test.
- Nrf2 Another way of identifying ASD phenotype 1 patients is to check for upregulation of Nrf2.
- the person skilled in the art is well aware of how upregulation of a specific gene such as Nrf2 may be checked. For example, it may be checked on the mRNA level using quantitative PRC techniques such as qPCR or RT-qPCR.
- upregulation of a gene may be determined on the protein level using protein quantification techniques such as Western Blot and quantitative dot blots. Upregulation is understood to mean an increase of mRNA levels or protein levels of at least 20% when compared to samples from healthy subjects.
- Variation in ASD severity is herein defined as the variation in severity of both ASD core and ancillary symptoms in a patient, which may be caused by fever, environmental factors such as temperature changes, infections, or allergic episodes.
- ASD core symptoms include but are not limited to social-interaction difficulties, communication challenges and a tendency to engage in repetitive behavior.
- ASD ancillary symptoms include but are not limited to intellectual disability, learning disability, genitourinary organ dysfunction (i.e. impairment to initiate urinating), episodes of diarrhea.
- monitoring of variation in ASD severity comprises measuring protein kinase levels in at least two samples of the ASD or ASD phenotype 1 patient.
- the present invention relates to protein kinase A for use in monitoring efficacy of an ASD treatment in an ASD phenotype 1 patient, wherein protein kinase A levels are measured in a sample of the patient and wherein a positive response to the ASD treatment is characterized by an increase of protein kinase A levels in comparison to baseline protein kinase A levels of the patient prior to treatment.
- the present invention is useful for monitoring efficacy of an ASD treatment in ASD phenotype 1 patients.
- successful and effective treatment of ASD will increase levels of protein kinase A. Consequently, a positive response to the treatment is characterized by an increase of protein kinase A levels in comparison to baseline protein kinase A levels of the patient prior to treatment.
- An insufficient response is characterized by the absence of an increase of and a cessation of response is characterized by a decrease in protein kinase A levels compared to levels of protein kinase A measured in the patient during a positive response.
- treatment may be maintained in the case of a positive response or may be increased in case of an insufficient response or cessation of response. In the case of an insufficient response or cessation of response, treatment may also be replaced with a different treatment.
- ASD treatment refers to any treatment for ASD known to the skilled person.
- ASD treatment include administration of risperidone, aripiprazole, clozapine, haloperidol, sertraline, oxytocin, secretin, methylphenidate, venlafaxine, fluoxetine, citalopram, bumetanide, memantine, rivastigmine, mirtazapine, melatonin, acamprosate, atomoxetine, intrathecal baclofen, DMXB-A (a derivative of the nemertine toxin anabasein), EPI-743: vincerinone, RG7314: antagonist of the V1A vasopressin receptor, sulforaphane, suramin. Additionally, possible treatments to be monitored with the present invention can be found in EP18204763.9.
- the present invention relates to a method for diagnosing ASD phenotype 1 in an ASD patient, the method comprising
- the present invention relates to a method for monitoring variation in ASD severity in an ASD phenotype 1 patient, the method comprising
- the present invention relates to a method for monitoring efficacy of an ASD treatment in an ASD phenotype 1 patient, the method comprising
- the present invention provides a kit for use in diagnosing ASD phenotype 1 in an ASD patient, the kit comprising means to measure protein kinase A levels in a sample of the patient.
- the present invention provides a kit for use in monitoring ASD disease activity in an ASD phenotype 1 patient, the kit comprising means to measure protein kinase A levels in a sample of the patient.
- the present invention provides a kit for use in monitoring efficacy of an ASD treatment in an ASD phenotype 1 patient, the kit comprising means to measure protein kinase A levels in a sample of the patient.
- the means for measuring protein kinase A levels in a sample may for example comprise anti-protein kinase A-antibodies.
- the kit according to the present invention may also comprise suitable buffers, detection agents and charts with reference values.
- Serum samples from three patients with ASD were collected at two different points. The first round of serum samples was collected prior to treatment and represented baseline values prior to treatment. The second round of serum samples were collected after 1 month of treatment, wherein ibudilast at a total dosage of 0.6 mg/kg 3 times/day was administered in conjunction with bumetanide at a total daily dosage of 0.08 mg/kg administered in two daily intakes.
- Protein kinase A levels of serum samples were measured using the MESACUP Protein Kinase Assay Kit (Medical & Biological laboratories CO., LTD) The assay was conducted according to the specification provided by the manufacturer.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
- The present invention relates to a biomarker assay for use in monitoring autism spectrum disorders (ASD), in particular ASD phenotype 1. Furthermore, the assay of the invention is also useful for diagnosing ASD phenotype 1.
- The cAMP-dependent protein kinase (PKA) is activated by the binding of cAMP to the regulatory subunit (R), of the molecule and results in the release of the active catalytic kinase subunit (C). Most of the effects of cAMP in eukaryotic systems are the result of phosphorylation of proteins at serine or threonine residues by PKA. There are several isoforms of both subunits of PKA. PKA is localized subcellularly by binding to multidomain scaffolding proteins known as AKAPs which bind to the R subunits of the holoenzyme (Pearce, L. R., D. Komander, and D. R. Alessi, The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol, 2010. 11 (1): p. 9-22). PKA plays a key role in neurodevelopment.
- Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders frequently characterized by impairments in social interactions, difficulties with language and communication, and the presence of repetitive, perseverative behaviors (Abrahams B S, Geschwind D H; Advances in autism genetics: on the threshold of a new neurobiology; Nat Rev Genet. 2008 June; 9(6):493), (Zoghbi H Y, Bear M F; Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities; Cold Spring Harb Perspect Biol. 2012 Mar. 1; 4(3)). Characteristic symptoms or behavioral traits of ASD typically appear during the first three years of life and remain present throughout life in the vast majority of patients. Intensity of symptoms may vary from patient to patient and may decrease as the patient develops adaptative skills. Environmental factors, Developmental (transition to puberty . . . ) or comorbidities such as epilepsia can also result in a worsening of symptoms.
- According to the fifth edition of the diagnostic and statistical manual of mental disorders (DSM. 5th Edition. Washington, D.C.: American Psychiatric Association; 2013. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders), ASD is characterized by two sets of core impairments: persisting deficits of social communication and interaction and restricted and repetitive behaviors, interests, activities. Compared to the previous edition (DSM-IV-Text Revision) (DSM-IV-TR 4th Edition. Washington, D.C.: American Psychiatric Association; 2000. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders.) DSM-5 introduced significant changes. In the diagnostic criteria, language abilities not employed in social communication have been de-emphasized. Further, the diagnostic subcategories, namely autistic disorder, Asperger disorder, Rett disorder, childhood disintegrative disorder, and pervasive developmental disorder (PDD) not otherwise specified are now encompassed by the diagnostic criteria for autism spectrum disorder. DSM-5 additionally requires to specify where patient fits within three levels of increasing severity of ASD, from (1) (“requiring support”) to (2) (“requiring substantial support”) up to (3) (“requiring very substantial support”).
- Other related behaviorally based definitions for Autism are proposed under various terminologies in other diagnostic manuals and classification system including the WHO-ICD-10 definition of Autistic Disorder (2017/18 ICD-10-CM Diagnosis Code F84.0)(World Health Organization. (1992). The ICD-10 classification of mental and behavioral disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization.).
- Evidence has recently accumulated to support the theory that the ever-expanding number of ASD susceptibility genes could in fact converge towards a limited number of molecular pathways. This growing assumption offers important translational opportunities as genes mediating synaptic and circuit formation or synaptic transmission are also involved in other physiological processes including modulation of the adaptive and innate immune response (Myka L. Estes M L, McAllister A K (2015), Nature Reviews Neuroscience 16, 469-486), cell proliferation, survival and protein synthesis (Subramanian M, Timmerman C K, Schwartz J L, Pham D L and Meffert M K (2015), Front. Neurosci. 9:313. Tang G. et al. (2014), Neuron. 83, 1131-1143.).
- However, there is a growing recognition by the scientific community that the behavioral based DSM-5 diagnosis of ASD does not allow for reasonable classification in terms of molecular and genetic alterations, but rather serves as a behavior based umbrella term for a large group of disorders with different etiology. These differences are caused by specific variations in genetic alterations and gene expression patterns.
- Attempts have been previously made to stratify ASD patients into smaller, more homogeneous subgroups by utilizing specific genetic signatures (Bernier et al; Disruptive CHD8 mutations define a phenotype of autism early in development; Cell 2014 Jul. 17; 158 (2): 263-276.) or behavioral and clinical endophenotypes (Eapen V. and Clarke R. A.; Autism Spectrum Disorder: From genotypes to phenotypes; Front Hum Neurosci. 2014; 8:914). However, these strategies face difficulty encompassing the genetic and phenotypic heterogeneity of ASD, and may not assist in the identification of specific neurobiological pathways underlying disease.
- Assays on a molecular basis might provide a way to classify ASD patients or monitor the course of their disease. However, because of the intrinsic complexity of ASD—and the complex intertwining of genetic and environmental causal factors, specific biomarkers for ASD have yet to be identified which could be used to establish such an assay.
- The problem to be solved is thus the provision of means to efficiently and easily identify phenotypes of ASD patients and monitor the activity of their disease with the help of easy-to-use biomarker assays.
- The present invention solves this problem by providing protein kinase A for use in diagnosing autism spectrum disorder (ASD) phenotype 1 in an ASD patient wherein protein kinase A levels are measured in a sample of the patient and wherein ASD phenotype 1 is diagnosed if the measured protein kinase A levels are lower than protein kinase A levels in an age and sex-matched control sample.
- Likewise, the problem is solved by protein kinase A for use in monitoring variation in ASD severity in an ASD patient, wherein protein kinase A levels are measured in a sample of the patient and wherein an increase in ASD severity is characterized by a decrease of protein kinase A levels compared to protein kinase A levels measured in previous samples of the patient.
- Thirdly, the problem is solved by a method for diagnosing ASD phenotype 1 in an ASD patient, the method comprising
-
- providing a sample of the patient, and
- measuring protein kinase A levels in the sample, and
- diagnosing ASD phenotype 1 if the protein kinase A levels measured in the sample are lower than protein kinase A levels in an age- and sex-matched control sample.
- Furthermore, the problem is solved by a method for monitoring variation in ASD severity in an ASD phenotype 1 patient, the method comprising
-
- providing a sample of the patient, and
- measuring protein kinase A levels in the sample.
- Lastly, the problem is solved by a method for monitoring efficacy of an ASD treatment in an ASD phenotype 1 patient, the method comprising
-
- providing a sample of the patient, and
- measuring protein kinase A levels in the sample.
- In one aspect, the present invention relates to protein kinase A for use in diagnosing autism spectrum disorder (ASD) phenotype 1 in an ASD patient wherein protein kinase A levels are measured in a sample of the patient and wherein ASD phenotype 1 is diagnosed if the measured protein kinase A levels are lower than protein kinase A levels in an age and sex-matched control sample.
- As used herein, the term autism spectrum disorder (ASD) is understood to cover a family of neurodevelopmental disorders characterized by deficits in social communication and interaction and restricted, repetitive patterns of behavior, interests or activities. In the following, the terms “autism spectrum disorder”, “autism” and “ASD” are used interchangeably.
- The person skilled in the art is well aware of how a patient may be diagnosed with ASD. For example, the skilled person may follow the criteria set up in “American Psychiatric Association; Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Fifth edition” to give a subject a diagnosis of ASD. Likewise, ASD patients may have been diagnosed according to standardized assessments tools including but not limited to DSM IV, ICD-9, ICD-10, DISCO, ADI-R, ADOS, CHAT.
- In other cases, patients may have a well-established DSM-IV diagnosis of autistic disorder, Asperger's disorder, or pervasive developmental disorder not otherwise specified (PDD-NOS).
- Protein kinase A is a family of cAMP-dependent protein kinases consisting of two catalytic and two regulatory subunits. As understood herein, the term “protein kinase A” covers any member of this enzyme family. In particular, the term is understood to refer to the two major types of mammalian protein kinase A, type I and type II (PKA I and PKA II). These kinases are distinguished by the presence of different R subunits termed RI and RII. Through biochemical studies and gene cloning, three isoforms of the C subunit, Cα, Cβ, and Cγ, and four isoforms of the R subunits, RIα, RIβ, RIIα, and RIIβ, have been identified. The present invention envisages not only measurement of holoenzyme of protein kinase A, but also of each of the subunits. In a preferred embodiment isoenzyme protein kinase A located in serum is measured.
- Measurement of protein kinase A can be performed using any method known to the skilled person. Examples of measurement methods include immunoassays, immunofluorescence assays, enzyme-linked immunosorbent assays (ELISA), lateral flow assays, radioimmunoassays (RIA) and magnetic immunoassays (MIA). In a preferred embodiment, protein kinase A levels are measured using a modified MESACUP Protein Kinase A Activity Assay. In another preferred embodiment, protein kinase A levels are measured by ELISA using an anti-protein kinase A-antibody.
- The sample of the patient may be any sample of a body fluid. In a preferred embodiment, the sample is selected from a blood sample, serum sample, plasma sample, saliva sample, a urine sample. The sample may have been processed to facilitate measurement of protein kinase A, e.g., by purification or by separation of individual components in the case of a whole-blood sample.
- The term “age and sex-matched control sample” refers to a sample taken from an individual or a group of healthy subjects having an age and sex corresponding to the ASD patient. In order to perform the present invention, it is not necessary measure protein kinase A levels of the control sample anew each time the present invention is performed. Instead, the present invention envisages the possibility to compare the measured value for protein kinase A levels of the respective ASD patient to mean reference values which have been determined for a large cohort group.
- The present invention is useful for diagnosing ASD phenotype 1 in ASD patients. ASD phenotype 1 patients can be defined by the following clinical signs and symptoms: having: 1) at least 1 mandatory characteristics: enlarged head size verses control population characterized by at least one standard deviation above the mean head circumference (HC) at 24 months and/or formal macrocephaly (HC>97% of the general population) and/or cyclical aggravation of core or ancillary autism symptoms potentiated by periods of infectious events, deciduous tooth loss, post-traumatic injury, endogenous and exogenous temperature variation; 2) and at least 2, most preferably at least 3 of the following 20 characteristics: accelerated hair and nail growth versus control population; Increased tendency to present with lighter colors of skin and eyes as compared to individuals of the same ethnicity; Substantially longer eyelashes than control subjects of the same ethnicity; At least 5 non-contiguous areas of hypopigmented skin, particularly presenting on the back of the patient; Signs of edema during periods of infectious events, deciduous tooth loss, post-traumatic injury, or endogenous and exogenous factors modifying body temperature; more specifically, facial edema located in the periorbital and forehead areas; Increased blood levels of gamma-glutamyl transpeptidase (GGT) as compared to typically developing individuals of the same age and ethnicity; Congenital genitourinary malformations and/or functional impairment to initiate urinating; Hypoplasia of the patella; Frequent episodes of diarrhea specifically before the age of 5 years; Frequent episodes of tinnitus; Thinning of the corpus callosum; Positive family history for hematological malignancies in particular but not limited to myeloma and acute promyelocytic leukemia; Positive family history for rheumatoid arthritis, that is at least two affected first-degree relatives in two consecutive generations; Adverse events in response to acetyl-salicylic acid or its derivatives; Iris coloboma, either monolateral or bilateral; Sleep hyperhidrosis particularly in newborns, toddlers and young children (notably increased night sweating during infancy and childhood often reported by relatives to requires bed linen changes); Increased Th1/Th2 ratio (i.e. elevated levels of Interleukin 1 beta, Interleukin 6, TNF-alpha, Interferon gamma); Congenital accessory or duplicated spleen; Congenital absence of the cisterna chyli; Reported history of mother suffering from viral or bacterial infection during pregnancy and/or biologically confirmed Maternal immune activation during pregnancy.
- Likewise, ASD phenotype 1 patients can be characterized by upregulation of Nrf2 transcriptional factor and clinical signs of heightened expression of proliferation-associated pathways. At the same time, these patients show an upregulation of pathways involved in adaptation to stress, apoptosis or cell differentiation, cell proliferation, cell cycle progression, cell division and differentiation (in particular but not limited to PI3K, AKT, mTOR/MAPK, ERK/JNK-P38).
- In this phenotype of patients, proinflammatory cytokines (TNF-α, IL-6, IL-1β, IL-17A, IL-22 and GM-CSF), Th1 cytokine (INF-γ) and chemokine (IL-8) may be significantly increased in the brain compared to healthy control patients. Th2 cytokines (IL-4, IL-5 and IL-10) may not show a significant difference. The Th1/Th2 ratio may be significantly increased in phenotype 1 patients.
- While the above clinical signs and symptoms provide a hint for the presence of ASD phenotype 1 in an ASD patient, the present invention provides for the first time a biomarker that can be used to identify and/or diagnose ASD phenotype 1 in an ASD patient. Consequently, the present invention provides a fast and easy method for the identification of ASD phenotype 1 patients.
- In another embodiment, the present invention also relates to protein kinase A for use in monitoring variation in ASD severity in an ASD patient, wherein protein kinase A levels are measured in a sample of the patient and wherein an increase in ASD severity is characterized by a decrease of protein kinase A levels compared to protein kinase A levels measured in previous samples of the patient.
- In a preferred embodiment, the present invention provides protein kinase A for use in monitoring variation in ASD severity in an ASD phenotype 1 patient. In addition to the methods according to the present invention, ASD phenotype 1 patients may also be identified with the help of a challenge test as described in PCT/EP2018/080372. Briefly, the concept of a challenge test is based on administration of an Nrf2-activator to an ASD patient. In ASD phenotype 1 patients, who already show an upregulation of the respective pathways, further activation of Nrf2 will lead to a worsening of core symptoms. Consequently, ASD phenotype 1 patients may be identified by a negative response in a challenge test.
- Another way of identifying ASD phenotype 1 patients is to check for upregulation of Nrf2. The person skilled in the art is well aware of how upregulation of a specific gene such as Nrf2 may be checked. For example, it may be checked on the mRNA level using quantitative PRC techniques such as qPCR or RT-qPCR. Likewise, upregulation of a gene may be determined on the protein level using protein quantification techniques such as Western Blot and quantitative dot blots. Upregulation is understood to mean an increase of mRNA levels or protein levels of at least 20% when compared to samples from healthy subjects.
- Variation in ASD severity is herein defined as the variation in severity of both ASD core and ancillary symptoms in a patient, which may be caused by fever, environmental factors such as temperature changes, infections, or allergic episodes. ASD core symptoms include but are not limited to social-interaction difficulties, communication challenges and a tendency to engage in repetitive behavior. ASD ancillary symptoms include but are not limited to intellectual disability, learning disability, genitourinary organ dysfunction (i.e. impairment to initiate urinating), episodes of diarrhea.
- In ASD phenotype 1 patients, an increase in ASD severity is accompanied and, in some cases, preceded by a decrease in protein kinase A levels. Consequently, the present invention is useful for monitoring variations in ASD severity in ASD patients, preferably in ASD phenotype 1 patients, by measuring protein kinase A levels in a sample of the patient, wherein an increase in ASD severity is characterized by lower levels of protein kinase A compared to protein kinase A levels measured in previous samples of the patient. In a preferred embodiment, monitoring of variation in ASD severity according to the present invention comprises measuring protein kinase levels in at least two samples of the ASD or ASD phenotype 1 patient.
- In yet another embodiment, the present invention relates to protein kinase A for use in monitoring efficacy of an ASD treatment in an ASD phenotype 1 patient, wherein protein kinase A levels are measured in a sample of the patient and wherein a positive response to the ASD treatment is characterized by an increase of protein kinase A levels in comparison to baseline protein kinase A levels of the patient prior to treatment.
- The present invention is useful for monitoring efficacy of an ASD treatment in ASD phenotype 1 patients. In ASD phenotype 1 patients, successful and effective treatment of ASD will increase levels of protein kinase A. Consequently, a positive response to the treatment is characterized by an increase of protein kinase A levels in comparison to baseline protein kinase A levels of the patient prior to treatment. An insufficient response is characterized by the absence of an increase of and a cessation of response is characterized by a decrease in protein kinase A levels compared to levels of protein kinase A measured in the patient during a positive response. Depending on whether a positive response or an insufficient response or a cessation of response is determined in the patient, treatment may be maintained in the case of a positive response or may be increased in case of an insufficient response or cessation of response. In the case of an insufficient response or cessation of response, treatment may also be replaced with a different treatment.
- As used herein, the term “ASD treatment” refers to any treatment for ASD known to the skilled person. Examples of ASD treatment include administration of risperidone, aripiprazole, clozapine, haloperidol, sertraline, oxytocin, secretin, methylphenidate, venlafaxine, fluoxetine, citalopram, bumetanide, memantine, rivastigmine, mirtazapine, melatonin, acamprosate, atomoxetine, intrathecal baclofen, DMXB-A (a derivative of the nemertine toxin anabasein), EPI-743: vincerinone, RG7314: antagonist of the V1A vasopressin receptor, sulforaphane, suramin. Additionally, possible treatments to be monitored with the present invention can be found in EP18204763.9.
- In another embodiment, the present invention relates to a method for diagnosing ASD phenotype 1 in an ASD patient, the method comprising
-
- providing a sample of the patient, and
- measuring protein kinase A levels in the sample, and
- diagnosing ASD phenotype 1 if the protein kinase A levels measured in the sample are lower than protein kinase A levels in an age- and sex-matched control sample.
- In yet another embodiment, the present invention relates to a method for monitoring variation in ASD severity in an ASD phenotype 1 patient, the method comprising
-
- providing a sample of the patient, and
- measuring protein kinase A levels in the sample.
- In yet another embodiment, the present invention relates to a method for monitoring efficacy of an ASD treatment in an ASD phenotype 1 patient, the method comprising
-
- providing a sample of the patient, and
- measuring protein kinase A levels in the sample.
- In another embodiment, the present invention provides a kit for use in diagnosing ASD phenotype 1 in an ASD patient, the kit comprising means to measure protein kinase A levels in a sample of the patient.
- In yet another embodiment, the present invention provides a kit for use in monitoring ASD disease activity in an ASD phenotype 1 patient, the kit comprising means to measure protein kinase A levels in a sample of the patient.
- In another embodiment, the present invention provides a kit for use in monitoring efficacy of an ASD treatment in an ASD phenotype 1 patient, the kit comprising means to measure protein kinase A levels in a sample of the patient.
- The means for measuring protein kinase A levels in a sample may for example comprise anti-protein kinase A-antibodies. Additionally, the kit according to the present invention may also comprise suitable buffers, detection agents and charts with reference values.
- Serum samples from three patients with ASD (diagnosed based on DSM-5 criteria) were collected at two different points. The first round of serum samples was collected prior to treatment and represented baseline values prior to treatment. The second round of serum samples were collected after 1 month of treatment, wherein ibudilast at a total dosage of 0.6 mg/kg 3 times/day was administered in conjunction with bumetanide at a total daily dosage of 0.08 mg/kg administered in two daily intakes.
- Protein kinase A levels of serum samples were measured using the MESACUP Protein Kinase Assay Kit (Medical & Biological laboratories CO., LTD) The assay was conducted according to the specification provided by the manufacturer.
- Three patients were classified as ASD Phenotype 1 is they showed:
-
- at least 1 mandatory characteristics:
- enlarged head size versus control population characterized by at least one standard deviations above the mean head circumference at 24 months and/or formal macrocephaly (HC>97% of the general population) and/or
- cyclical aggravation of core or ancillary autism symptoms potentiated by periods of infectious events, deciduous tooth loss, post-traumatic injury, endogenous and exogenous temperature variation and
- at least 2, and most preferably at least 3 of the following 20 characteristics:
- Accelerated hair and nail growth versus control population
- Increased tendency to present with lighter colors of skin and eyes as compared to individuals of the same ethnicity
- Substantially longer eyelashes than control subjects of the same ethnicity
- At least 5 non-contiguous areas of hypopigmented skin, particularly presenting on the back of the patient
- Signs of edema during periods of infectious events, deciduous tooth loss, post-traumatic injury, or endogenous and exogenous factors modifying body temperature; more specifically, facial edema located in the periorbital and forehead areas
- Increased blood levels of gamma-glutamyl transpeptidase (GGT) as compared to typically developing individuals of the same age and ethnicity
- Congenital genitourinary malformations and/or functional impairment to initiate urinating
- Hypoplasia of the patella
- Frequent episodes of diarrhea specifically before the age of 5 years
- Frequent episodes of tinnitus
- Thinning of the corpus callosum
- Positive family history for hematological malignancies in particular but not limited to myeloma and acute promyelocytic leukemia
- Positive family history for rheumatoid arthritis, that is at least two affected first-degree relatives in two consecutive generations
- Adverse events in response to acetyl-salicylic acid or its derivatives
- Iris coloboma, either monolateral or bilateral
- Sleep hyperhidrosis particularly in newborns, toddlers and young children (notably increased night sweating during infancy and childhood often reported by relatives to requires bed linen changes)
- Increased Th1/Th2 ratio (i.e. elevated levels of Interleukin 1 beta, Interleukin 6, TNF-alpha, Interferon gamma)
- Congenital accessory or duplicated spleen
- Congenital absence of the cisterna chyli
- Reported history of mother suffering from viral or bacterial infection during pregnancy and/or biologically confirmed Maternal immune activation during pregnancy
- at least 1 mandatory characteristics:
- Results of the assay are presented below in table 2.
-
TABLE 2 PKA measurement before and after treatment with ibudilast at a total dosage of 0.6 mg/kg 3 times/day in conjunction with bumetanide at a total dosage of 0.08 mg/kg 2 times/day PKA value Patient 1 Patient 3 Patient 4 Before 3.9 ng/ml 5 ng/ml 5.1 ng/ml treatment (claim 3) After 12.4 ng/ml 14.8 ng/ml 14.8 ng/ml treatment (claim 3)
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/761,926 US20200325519A1 (en) | 2017-11-06 | 2018-11-06 | Biomarker assay for use in monitoring autism |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762582213P | 2017-11-06 | 2017-11-06 | |
EP17200220.6A EP3480597A1 (en) | 2017-11-06 | 2017-11-06 | Biomarker assay for use in monitoring autism |
EP17200220.6 | 2017-11-06 | ||
US16/761,926 US20200325519A1 (en) | 2017-11-06 | 2018-11-06 | Biomarker assay for use in monitoring autism |
PCT/EP2018/080375 WO2019086724A1 (en) | 2017-11-06 | 2018-11-06 | Biomarker assay for use in monitoring autism |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2018/080375 A-371-Of-International WO2019086724A1 (en) | 2017-11-06 | 2018-11-06 | Biomarker assay for use in monitoring autism |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/470,985 Continuation US20240011071A1 (en) | 2017-11-06 | 2023-09-20 | Biomarker assay for use in monitoring autism |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200325519A1 true US20200325519A1 (en) | 2020-10-15 |
Family
ID=60515089
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/761,926 Abandoned US20200325519A1 (en) | 2017-11-06 | 2018-11-06 | Biomarker assay for use in monitoring autism |
US18/470,985 Pending US20240011071A1 (en) | 2017-11-06 | 2023-09-20 | Biomarker assay for use in monitoring autism |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/470,985 Pending US20240011071A1 (en) | 2017-11-06 | 2023-09-20 | Biomarker assay for use in monitoring autism |
Country Status (9)
Country | Link |
---|---|
US (2) | US20200325519A1 (en) |
EP (2) | EP3480597A1 (en) |
JP (1) | JP7134505B2 (en) |
KR (1) | KR102373117B1 (en) |
CN (1) | CN111556969A (en) |
AU (2) | AU2018359720A1 (en) |
CA (1) | CA3081903A1 (en) |
IL (1) | IL274477A (en) |
WO (1) | WO2019086724A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4012414A1 (en) * | 2020-12-11 | 2022-06-15 | Stalicla S.A. | Diagnosis of autism spectrum disorder phenotype 1 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023198176A1 (en) * | 2022-04-15 | 2023-10-19 | Xinhua Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Prediction of the treatment response to bumetanide in subject with autism spectrum disorder |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100746961B1 (en) * | 2006-07-31 | 2007-08-07 | 한국과학기술연구원 | Biosensor for the detection of protein kinase a and kit comprising the same |
US20110183904A1 (en) * | 2008-04-10 | 2011-07-28 | The Children's Mercy Hospital | Methods and compositions for altering behavior associated with autism spectrum disorder |
US20150259740A1 (en) * | 2011-09-14 | 2015-09-17 | Harvey Pollard | Processes and kits to detect and monitor for diagnostic biomarkers for post traumatic stress disorder (ptsd) and to differentiate between suicidal and non-suicidal form of the disorder |
WO2013066972A1 (en) * | 2011-10-31 | 2013-05-10 | Children's Medical Center Corporation | Methods and compositions for characterizing autism spectrum disorder based on gene expression patterns |
EP3084007A4 (en) * | 2013-12-20 | 2017-09-27 | Lineagen, Inc. | Diagnosis and prediction of austism spectral disorder |
CA3023014C (en) | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
-
2017
- 2017-11-06 EP EP17200220.6A patent/EP3480597A1/en not_active Withdrawn
-
2018
- 2018-11-06 KR KR1020207016190A patent/KR102373117B1/en active IP Right Grant
- 2018-11-06 CA CA3081903A patent/CA3081903A1/en active Pending
- 2018-11-06 CN CN201880085494.4A patent/CN111556969A/en active Pending
- 2018-11-06 JP JP2020526315A patent/JP7134505B2/en active Active
- 2018-11-06 AU AU2018359720A patent/AU2018359720A1/en not_active Abandoned
- 2018-11-06 WO PCT/EP2018/080375 patent/WO2019086724A1/en unknown
- 2018-11-06 US US16/761,926 patent/US20200325519A1/en not_active Abandoned
- 2018-11-06 EP EP18795690.9A patent/EP3707512A1/en active Pending
-
2020
- 2020-05-05 IL IL274477A patent/IL274477A/en unknown
-
2022
- 2022-05-27 AU AU2022203618A patent/AU2022203618A1/en active Pending
-
2023
- 2023-09-20 US US18/470,985 patent/US20240011071A1/en active Pending
Non-Patent Citations (2)
Title |
---|
Russo, A.J., et al. 2017 Acad J Ped Neonatol 5(3): 555721, pages 0057-0060. (Year: 2017) * |
Schaefer, G.B., et al. 2008 Genet Med 10(1): 4-12. (Year: 2008) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4012414A1 (en) * | 2020-12-11 | 2022-06-15 | Stalicla S.A. | Diagnosis of autism spectrum disorder phenotype 1 |
WO2022123057A1 (en) * | 2020-12-11 | 2022-06-16 | Stalicla Sa | Diagnosis of autism spectrum disorder |
Also Published As
Publication number | Publication date |
---|---|
EP3707512A1 (en) | 2020-09-16 |
AU2018359720A1 (en) | 2020-05-28 |
CA3081903A1 (en) | 2019-05-09 |
KR102373117B1 (en) | 2022-03-10 |
EP3480597A1 (en) | 2019-05-08 |
US20240011071A1 (en) | 2024-01-11 |
JP2021505847A (en) | 2021-02-18 |
KR20200108274A (en) | 2020-09-17 |
WO2019086724A1 (en) | 2019-05-09 |
AU2022203618A1 (en) | 2022-06-16 |
CN111556969A (en) | 2020-08-18 |
IL274477A (en) | 2020-06-30 |
JP7134505B2 (en) | 2022-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Moaaz et al. | Th17/Treg cells imbalance and their related cytokines (IL-17, IL-10 and TGF-β) in children with autism spectrum disorder | |
Minakova et al. | Maternal immune activation, central nervous system development and behavioral phenotypes | |
Soorya et al. | Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency | |
Ashwood et al. | Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome | |
Newschaffer et al. | Heritable and nonheritable risk factors for autism spectrum disorders | |
US20240011071A1 (en) | Biomarker assay for use in monitoring autism | |
Moieni et al. | Inflammation impairs social cognitive processing: a randomized controlled trial of endotoxin | |
Mäki et al. | Predictors of schizophrenia—a review | |
Abreu et al. | Central precocious puberty caused by mutations in the imprinted gene MKRN3 | |
Corcoran et al. | HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia | |
Torres et al. | How do hypothalamic nonapeptides shape youth’s sociality? A systematic review on oxytocin, vasopressin and human socio-emotional development | |
Hu et al. | Alterations in plasma cytokine levels in chinese children with autism spectrum disorder | |
Torrey et al. | Autism and head circumference in the first year of life | |
US20140018446A1 (en) | Serum Biomarker Screen for the Diagnosis of Clinical and Preclinical Alzheimer's Disease | |
Erlenmeyer-Kimling et al. | Early life precursors of psychiatric outcomes in adulthood in subjects at risk for schizophrenia or affective disorders | |
Ahmad et al. | Elevated IL-16 expression is associated with development of immune dysfunction in children with autism | |
Yang et al. | Mutant BCL11B in a patient with a neurodevelopmental disorder and T-cell abnormalities | |
Wang et al. | TSLP polymorphisms, allergen exposures, and the risk of atopic disorders in children | |
Hayashi et al. | KIBRA genetic polymorphism influences episodic memory in Alzheimer’s disease, but does not show association with disease in a Japanese cohort | |
Ahmad et al. | Dysregulation of the expression of HLA-DR, costimulatory molecule, and chemokine receptors on immune cells in children with autism | |
Çelikkol Sadıç et al. | Evaluation of Appetite-Regulating Hormones ın Young Children with Autism Spectrum Disorder | |
Carter et al. | Maternal immune activation and interleukin 17A in the pathogenesis of autistic spectrum disorder and why it matters in the COVID-19 era | |
Coutinho et al. | Autoimmunity in neuropsychiatric disorders | |
US20140072982A1 (en) | Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases | |
Marneros et al. | The concept of distinct but voluminous groups of bipolar and unipolar diseases: I. Bipolar diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: STALICLA SA, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DURHAM, LYNN;REEL/FRAME:053602/0918 Effective date: 20200608 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |